Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ACET

Adicet Bio, Inc.

Healthcare | Biotechnology
$7.76 -0.35 (-4.32%) as of 2026-07-14 16:15 UTC
Market Cap$330M
Volume77.7K
EPS (TTM)$-1.70

Adicet Bio, Inc. (NASDAQ: ACET) is a $330M biotechnology company trading at $7.76 (−4.3% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 16:15 UTC.

52-Week Range
Low $6.01High $17.44

What Adicet Bio, Inc. does

This clinical stage biotechnology company develops allogeneic gamma delta T cell therapies designed to treat autoimmune diseases and cancer. The company's approach uses off-the-shelf gamma delta T cells engineered with chimeric antigen receptors that can be derived from unrelated donors, manufactured, stored, and administered without triggering immune rejection. The lead product candidate, prulacabtagene leucel, targets CD20 and is being evaluated in Phase 1 trials across multiple autoimmune conditions including lupus nephritis and systemic lupus erythematosus.

Summarized from Adicet Bio, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
Key facts
Quote
Price$7.76
Change (1D)-0.35 (-4.32%)
Market cap$330M
Volume77.7K shares
52-week range$6.01 – $17.44
Valuation
EPS (TTM)$-1.70
Price/book1.13×
Returns
52-week return+29.1%
Revenue, margins & earnings
FY2021: net loss $62M on revenue $10M$10MFY2021FY2022: net loss $70M on revenue $25M$25MFY2022
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-06-23
  • 2026-06-23Schor ChenPresident & CEOA55,000—
  • 2026-06-23Aftab BlakeChief Scientific OfficerA55,000—
  • 2026-06-23DUBIN STEVEA4,200—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • RA CAPITAL MANAGEMENT, L.P.1,182,624$8.05M+24.7%
  • ORBIMED ADVISORS LLC1,027,944$7.00M0.0%
  • FRANKLIN RESOURCES INC626,571$4.27M0.0%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Adicet Bio, Inc. do?

This clinical stage biotechnology company develops allogeneic gamma delta T cell therapies designed to treat autoimmune diseases and cancer.

What is ACET's valuation?

ACET trades at $7.76, as of 2026-07-14.

When did ACET last file with the SEC?

Adicet Bio, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 16:15 UTC. This page is also available as JSON at /api/data?ticker=ACET and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACET and 3,500+ tickers.

Create a free account — keep ACET
For your agent
GET /api/data?ticker=ACET

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt